Cosmo
Cosmo Pharmaceuticals NV is an Italian-founded specialty pharmaceutical company developing and manufacturing prescription medicines and AI-driven medical devices for gastroenterology and dermatology globally. The company formulates and manufactures gastrointestinal drugs using its MMX technology, including Lialda and Uceris for inflammatory bowel disease, alongside Winlevi for acne, and GI Genius AI endoscopy modules. Principal revenues derive from commercial pharmaceutical product sales, AI endoscopy hardware royalties, upfront licensing fees, and milestone payments from global marketing partners like Teva and Sun Pharma. Core end markets encompass gastroenterology specialty clinics, hospital endoscopy suites, dermatology practices, and prescription patients in North America and Europe. Cosmo Pharmaceuticals holds a market-leading global position in specialized oral drug delivery for gastrointestinal disorders. Incorporated in the Netherlands, headquartered in Dublin, Ireland, its shares trade on the SIX Swiss Exchange.
3 of the funds FundTelligence covers report a position in Cosmo.
- Legal name
- Cosmo NV
- Sector
- Health Care
- Country
- Netherlands
- Funds holding it
- 3
Funds holding Cosmo
- Lannebo Europa Småbolag — Lannebo · 1.15 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)